Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) announced on March 6, 2023, the granting of stock options for 15,200 shares to a new employee under their 2023 Inducement Plan. The options have an exercise price of $24.86, closing on March 1, 2023. The vesting schedule includes 25% vesting on the one-year anniversary, with the remaining shares vesting monthly over three years, contingent upon continued employment. Syndax focuses on developing cancer therapies including innovative drugs like revumenib and axatilimab, which are currently in pivotal trials.
Positive
- Inducement award for 15,200 shares reflects company growth and new hires.
- Stock options exercise price aligns with market value, which could be positive for employee retention and morale.
Negative
- None.
Details
News Market Reaction – SNDX
The recorded move for SNDX in the trading session of this news was -0.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the Menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.
Syndax Contact
Sharon Klahre
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301763791.html
SOURCE
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.